Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EIGR.US
id: 452, Created by Stan Vick Chase, Scout
Eiger Biopharmaceuticals Inc
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
On October 5, 2022, Eiger (EIGR) announced that it would not seek an EUA request for peginterferon lambda after the FDA had “denied the request for a pre-EUA meeting.”
Specifically, the Company disclosed that, “citing its concerns about the conduct of the TOGETHER study, the FDA concluded that any authorization request based on the data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic.”
Investors have reasons to suspect that the Company and its Leaders violated rights of shareholders by:
- overstating its expertise in regulatory drug development to investors.
- fail to properly assess problems with its TOGETHER trial and determine if the trial could support the peginterferon lambda EUA. Based on these problems with the trial, the FDA was unlikely to approve the Company’s EUA.
Alleged Offence
Misleading Statements,
Failure to Disclose,
Negligence,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
04 October 2022
Court
Northern District of California